Thanks for the link Reg and even though it was published two an an half years ago, two interesting extracts below, covering approval but not use in Canada/NZ and the US demand via the clinics, whilst FDA requests more data for MSB.
Prochymal from Osiris Therapeutics was granted conditional licensing approval to treat children suffering from acute graft vs. host disease (GvHD) in Canada in 2012 (Galipeau and Senséb, 2018; Chisholm et al., 2019). It was revealed in 2016 that Prochymal had not been utilized because it could not get reimbursed (David Gagnon, 2016; Galipeau and Senséb, 2018).
Global market demand for MSCs is expected to reach $7.5 billion USD by 2022, with the US expected to have the largest market share (34.3%) despite the fact that the US has yet to grant approval to an MSC product (Pereira Chilima et al., 2018).
- Forums
- ASX - By Stock
- 2023 The Final Countdown
Thanks for the link Reg and even though it was published two an...
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B |
Open | High | Low | Value | Volume |
95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 94461 | 95.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
96.0¢ | 61151 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 94461 | 0.950 |
6 | 59977 | 0.945 |
9 | 154571 | 0.940 |
4 | 44875 | 0.935 |
5 | 92633 | 0.930 |
Price($) | Vol. | No. |
---|---|---|
0.960 | 61151 | 6 |
0.965 | 46785 | 5 |
0.970 | 48228 | 6 |
0.975 | 64461 | 2 |
0.980 | 31269 | 3 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |